Featured Articles

Undecimal Bio: €16 Million to Advance Targeted RNA Medicines

Undecimal Bio is a Cambridge-based biotechnology company developing targeted delivery technologies for RNA medicines. Spun out of Eleven Therapeutics, the company is addressing a major challenge in RNA therapeutics: delivering a treatment to the intended cells and tissues rather than relying on the therapeutic molecule alone. Small interfering RNA (siRNA) can be used to silence

Latest Articles

No more posts to show